Scarica l'app Stockscreener
26.97
2.42%
-0.67
Dopo l'orario di chiusura:
26.82
-0.15
-0.56%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$27.64
Aprire:
$27.28
Volume 24 ore:
83,317
Relative Volume:
0.67
Capitalizzazione di mercato:
$408.87M
Reddito:
$138.20M
Utile/perdita netta:
$5.52M
Rapporto P/E:
70.97
EPS:
0.38
Flusso di cassa netto:
$9.86M
1 W Prestazione:
-13.28%
1M Prestazione:
-8.02%
6M Prestazione:
-28.39%
1 anno Prestazione:
-16.99%
Intervallo 1D:
$26.74
$28.10
Intervallo di 1 settimana:
$26.00
$31.22
Portata 52W:
$26.00
$42.44
Surmodics Inc Stock (SRDX) Company Profile
Nome
Surmodics Inc
Settore
Industria
Telefono
(952) 500-7000
Indirizzo
9924 W 74TH ST, EDEN PRAIRIE, MN
Confronta SRDX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SRDX
Surmodics Inc
|
26.97 | 408.87M | 138.20M | 5.52M | 9.86M | 0.38 |
|
ABT
Abbott Laboratories
|
132.60 | 224.65B | 42.34B | 13.50B | 6.66B | 7.71 |
|
BSX
Boston Scientific Corp
|
104.24 | 151.13B | 17.55B | 2.03B | 2.72B | 1.37 |
|
SYK
Stryker Corp
|
381.36 | 139.34B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
83.45 | 107.01B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
75.11 | 44.25B | 5.54B | 4.18B | 259.90M | 7.00 |
Surmodics Inc Stock (SRDX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-03-07 | Aggiornamento | Lake Street | Hold → Buy |
| 2023-06-13 | Aggiornamento | Needham | Hold → Buy |
| 2023-02-13 | Downgrade | Needham | Buy → Hold |
| 2020-07-23 | Aggiornamento | Needham | Hold → Buy |
| 2019-12-11 | Downgrade | Needham | Buy → Hold |
| 2019-11-01 | Downgrade | Lake Street | Buy → Hold |
| 2019-08-01 | Reiterato | Needham | Buy |
| 2019-05-02 | Reiterato | Lake Street | Buy |
| 2019-05-02 | Reiterato | Needham | Buy |
| 2019-02-21 | Reiterato | Needham | Buy |
| 2018-05-16 | Reiterato | Needham | Buy |
| 2018-03-01 | Aggiornamento | Sidoti | Neutral → Buy |
| 2018-02-28 | Reiterato | Lake Street | Buy |
| 2018-02-28 | Iniziato | Needham | Buy |
| 2017-07-14 | Iniziato | Lake Street | Buy |
| 2016-11-21 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| 2016-10-06 | Downgrade | Sidoti | Buy → Neutral |
| 2016-05-03 | Reiterato | Barrington Research | Outperform |
| 2015-08-06 | Reiterato | Barrington Research | Outperform |
| 2015-03-27 | Iniziato | Dougherty & Company | Buy |
| 2014-02-25 | Iniziato | Laidlaw | Buy |
| 2013-08-01 | Aggiornamento | Feltl & Co. | Buy → Strong Buy |
| 2012-11-12 | Reiterato | Barrington Research | Outperform |
Mostra tutto
Surmodics Inc Borsa (SRDX) Ultime notizie
Are Options Traders Betting on a Big Move in Surmodics Stock? - Yahoo Finance
SRDX Stock Down Following Q2 Earnings Miss, Gross Margin Contracts - TradingView
Surmodics Reports Q2 2025 Results Amid Acquisition Challenges - TipRanks
SurModics: Fiscal Q2 Earnings Snapshot - MySA
SurModics (SRDX) Reports Q2 Earnings: What Key Metrics Have to Say - Yahoo Finance
SurModics stock touches 52-week low at $26.21 amid market shifts - Investing.com
Surmodics (SRDX) Projects Declining Revenue for Fiscal 2025 | SR - GuruFocus
Surmodics Reports Second Quarter of Fiscal Year 2025 Financial Results; Introduces Fiscal Year 2025 Financial Guidance - BioSpace
Surmodics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
SurModics (SRDX) Reports Q2 Loss, Misses Revenue Estimates - Yahoo Finance
Surmodics (SRDX) Reports Lower Than Expected Q2 Revenue Amid Ant - GuruFocus
SURMODICS INC SEC 10-Q Report - TradingView
Surmodics Reports Second Quarter of Fiscal Year 2025 Financial R - GuruFocus
Surmodics Reports Second Quarter of Fiscal Year 2025 Financial Results; Introduces Fiscal Year 2025 Financial Guidance | SRDX Stock News - GuruFocus
Surmodics Reports Second Quarter Fiscal 2025 Financial Results - TradingView
A Look at Surmodics's Upcoming Earnings Report - Nasdaq
How To Trade (SRDX) - news.stocktradersdaily.com
Surmodics to Report Second Quarter of Fiscal 2025 Financial Results on April 30 - 01net
Surmodics to Report Second Quarter of Fiscal 2025 Financial Resu - GuruFocus
FTC Expands Lawsuit Against GTCR Over Surmodics Acquisition - MSN
Surmodics' SurVeil DCB Matches IN.PACT Admiral In Efficacy With Lower Drug Dose In Global Trial - Nasdaq
Surmodics (SRDX) Publishes Promising Clinical Trial Results for SurVeil DCB | SRDX Stock News - GuruFocus
Surmodics Announces Publication of TRANSCEND Trial, Highlighting - GuruFocus
Surmodics Announces Publication of TRANSCEND Trial, Highlighting Drug-Delivery Technology of its SurVeil™ Drug-Coated Balloon - Business Wire
Geode Capital Management LLC Sells 2,639 Shares of Surmodics, Inc. (NASDAQ:SRDX) - Defense World
Illinois, Minnesota join FTC challenge against $627M Surmodics buyout - MedTech Dive
Minnesota AG Ellison joins federal lawsuit to stop merger of companies that make medical device coatings - KIMT
Illinois joins FTC suit to block GTCR’s takeover of Surmodics - Crain's Chicago Business
AG Ellison Joins Suit to Block Surmodics Acquisition - Twin Cities Business
Corebridge Financial Inc. Lowers Stock Position in Surmodics, Inc. (NASDAQ:SRDX) - Defense World
(SRDX) Long Term Investment Analysis - news.stocktradersdaily.com
Surmodics Investigated by Block & Leviton For Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the Firm - ACCESS Newswire
SRDX Stock Dips Despite the Launch of Pounce XL Thrombectomy System - Yahoo Finance
Surmodics launches Pounce XL for peripheral artery clot removal By Investing.com - Investing.com South Africa
Surmodics launches Pounce XL thrombectomy system - Yahoo Finance
Surmodics launches Pounce XL for peripheral artery clot removal - Investing.com Australia
Revolutionary Blood Clot Treatment: Pounce XL Shows 80% Success Rate in Just 20 Minutes - Stock Titan
Gardner Lewis Asset Management L P Raises Position in Surmodics, Inc. (NASDAQ:SRDX) - MarketBeat
Learn to Evaluate (SRDX) using the Charts - news.stocktradersdaily.com
PE Firm Hits Back Against Medical Device Coating Challenge - Law360
FTC Challenges Medical Device Coatings Deal - Medical Product Outsourcing
Zacks Research Decreases Earnings Estimates for Surmodics - Defense World
Bank of New York Mellon Corp Sells 2,966 Shares of Surmodics, Inc. (NASDAQ:SRDX) - Defense World
Here's Why You Should Retain Surmodics Stock in Your Portfolio Now - Zacks Investment Research
FTC’s First Merger Challenge Under New Leadership Signals Return to Traditional Antitrust Theories in Private Equity Deals - JD Supra
GTCR / Surmodics: Four Key Takeaways for M&A Antitrust from the First FTC Merger Challenge Under Trump - JD Supra
FTC sues to block GTCR’s ‘unlawful acquisition’ of Surmodics - Yahoo Finance
Medical Coating Market Projected To Witness Substantial Growth, 2025-2032: Freudenberg Medical Europe GmbH, - EIN News
FTC Fights to Block Merger Threatening Healthcare Innovation and Patient-Critical Devices - MyChesCo
Surmodics (NASDAQ:SRDX) Stock Rating Upgraded by Lake Street Capital - Defense World
Surmodics Inc Azioni (SRDX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
11.62%
0.20%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):